Scientific and information message
under the new name
SANTO company informs that from July 2023, SANTO's ketoprofen range produced under the trade name Ketotop, will be produced under the new trade name Febrofid along with new registration certificates. Along with the new brand name, the packaging was also rebranded. The design of all forms of Febrofid has been made to the same standard. The above changes will not affect the availability of the different forms and dosages of the medicine for patients.
SANTO company informs that from July 2023, SANTO's ketoprofen range produced under the trade name Ketotop, will be produced under the new trade name Febrofid along with new registration certificates. Along with the new brand name, the packaging was also rebranded. The design of all forms of Febrofid has been made to the same standard. The above changes will not affect the availability of the different forms and dosages of the medicine for patients.
Since 2024, the Line of ketoprofen by SANTO will be supplied to treatment and preventive care facilities within the guaranteed volume of free medical care under the new trade name Febrofid. Forma of ketoprofen under the new trade name Febrofid produced Santo, with new packaging design, are available at the market in the following dosages:
| PREVIOUS LINE OF KETOPROFENS BY SANTO | NEW LINE OF KETOPROFENS BY SANTO |
| Ketotop 100 mg/2 ml solution for injection № 10 РК-ЛС-5№013002 | Febrofid 100 mg/2 ml solution for injection № 10 РК-ЛС-5№025390 |
| Ketotop 100 mg/2 ml solution for injection №5 РК-ЛС-5№013002 | Febrofid 100 mg/2 ml solution for injection №5 РК-ЛС-5№025390 |
| Ketotop Forte 100 mg №20 РК-ЛС-5№018346 | Febrofid Forte 100 mg №20 РК-ЛС-0№025728 |
| Ketotop 50 mg №20 РК-ЛС-5№018675 | Febrofid 50 mg №20 РК-ЛС-0№025727 |
The active substance ketoprofen is a non-steroidal anti-inflammatory agent belonging to the group of propionic acid derivatives and acting as a non-selective inhibitor of cyclooxygenase-1 and cyclooxygenase-2. It has a strong analgesic, anti-inflammatory and antipyretic effects and is intended for symptomatic treatment, reduction of pain and inflammation. Ketoprofen is included in the List of strategic important drugs and medical products. **********************************************************************************
SANTO Member of Polpharma Group
SANTO Member of Polpharma Group is a part of international pharmaceutical Group Polpharma, providing activity at the markets of Central and Eastern Europe, the Caucasus and Central Asia. The Company develops, produces and supplies affordable high-quality medicines to the markets of Kazakhstan and Central Asia. Nowadays, SANTO Member of Polpharma Group holds a leading position among Kazakhstan’s pharmaceutical manufacturers. The Company's portfolio includes more than 240 generic medicines in 12 pharmacotherapeutic groups for the treatment of diseases in various therapeutic areas.
The Company has established representative offices in Kyrgyzstan and Uzbekistan and exports to Russia and Mongolia, and meets the needs of the Kazakhstan market.
Additional information:
Tatiana Philipchik, Regional PR-manager
Tel. +77012111029
SANTO Company
e-mail: tatyana.filipchik@santo.kz